---
title: "Karyopharm治疗 (KPTI.US) — 财务报表"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/KPTI.US/norm.md"
symbol: "KPTI.US"
name: "Karyopharm治疗"
parent: "https://longbridge.com/zh-CN/quote/KPTI.US.md"
datetime: "2026-05-21T21:57:33.851Z"
locales:
  - [en](https://longbridge.com/en/quote/KPTI.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KPTI.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KPTI.US/norm.md)
---

# Karyopharm治疗 (KPTI.US) — 财务报表

## 利润表 (USD)

| 指标 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| 每股收益 | -1.24 | -5.71 | -3.82 | -4.32 | -2.77 |
| ROE | 32.07% | 145.43% | 52.15% | 67.00% | 47.89% |
| 营业收入 | 35.07M | 34.08M | 44.04M | 37.93M | 30.02M |
| 净利润 | -22.39M | -102.20M | -33.13M | -37.25M | -23.46M |
| 营业利润 | -26.76M | -17.84M | -15.22M | -24.39M | -33.26M |
| 毛利率 | 96.16% | 14.46% | 25.85% | 10.78% | -19.67% |
| 净利率 | -63.86% | -299.89% | -75.21% | -98.22% | -78.17% |
| 利润含金量 | - | - | - | - | - |

## 资产负债表 (USD)

| 指标 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| 资产与负债 | 131.42M | 108.42M | 96.23M | 104.88M | 127.71M |
| 权益乘数 | -0.4947 | -0.3701 | -0.3574 | -0.4390 | -0.6203 |
| 每股净资产 | -12.07 | -16.00 | -30.94 | -27.63 | -24.03 |
| 资产周转率 | 1.17 | 1.07 | 0.9977 | 0.8610 | 0.8557 |
| 现金及短投 | 90.85M | 63.74M | 45.88M | 51.70M | 69.94M |
| 存货与应收 | - | 4.04M | 3.97M | 4.99M | 4.77M |
| 长期投资 | - | 4.65M | 4.80M | 5.33M | 5.80M |
| 净债务 | 205.88M | 242.20M | 224.04M | 212.42M | 190.26M |

## 现金流量表 (USD)

| 指标 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| 经营现金流 | - | -11.83M | -5.86M | -18.70M | -38.98M |
| 投资现金流 | - | 5.00M | 4.80M | 18.29M | 15.29M |
| 融资现金流 | - | 29.69M | 0.0000 | 356000.00 | - |
| 自由现金流 | - | -6.17M | 2.10M | -5.14M | -22.08M |
| 现金流充裕率 | - | -4731.20% | - | - | - |
| 举债与偿债 | - | 27.25M | - | - | - |
| 资本支出 | - | - | - | - | - |